ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: cancer

All That Is Old—& New: Treatment Implications for Rheumatoid Arthritis

  |  

EULAR 2023 (MILAN)—Over the past several years, a plethora of new treatments for patients with rheumatoid arthritis (RA) has emerged, while older treatments still play a large role in therapy for many patients. At the EULAR 2023 session titled Rheumatoid Arthritis: New Small Molecules and Old DMARDs, several speakers presented abstracts comparing different treatment effects…

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

  |  

The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…

Late Summer 2023’s Awards, Appointments & Announcements in Rheumatology

  |  

PANLAR Names Eric L. Matteson, MD, a 2023 Master Throughout his career at the Mayo Clinic, Rochester, Minn., Eric L. Matteson, MD, currently professor of rheumatology, emeritus, actively engaged with his rheumatology colleagues in Latin America. He participated in conferences, worked on South American publications and brought rheumatology fellows to the Mayo Clinic for training….

Case Report: Giant Cell Arteritis-Related Stroke

Jessica Meek, MD, Anna Coppinger, DO, & Sejal Khan, DO  |  

Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

What Patients with Lupus Want You to Know

Jacqueline Jansz, MD, with Nadera Sweiss, MD  |  

During a series of interviews with patients who have systemic lupus erythematosus, issues related to medication side effects, supplement use, depression and support groups arose, as well as concerns about race and activities of daily living. The interviews gave me a better understanding of what patients with lupus wish their physicians knew. I am grateful…

Methotrexate Shortage: Why It’s Happening & Potential Solutions

  |  

In recent months, many rheumatologists and rheumatology professionals have noted issues related to obtaining supplies of injectable and oral methotrexate for their patients with rheumatoid arthritis (RA). A conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), methotrexate is available as both oral tablets and as a subcutaneous injection for the treatment of RA and other autoimmune diseases.1…